Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Clinical Therapeutics > Multiple Sclerosis > Flashcards

Multiple Sclerosis Flashcards

1
Q

What is MS

A

Multiple sclerosis (MS) is an acquired, chronic, immune-mediated, inflammatory condition of the central nervous system (CNS) that can affect the brain, brainstem, and spinal cord.

The inflammatory process causes areas of demyelination (damage to white matter), gliosis (scarring), and neuronal damage throughout the CNS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is myelin

A

Several layers of cytoplasmic membrane wrapped around axons.
Oligodendrocytes (central) or scwann cell (motor/peripheral)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is demyelination

A

Loss of myelin disrupting neuronal function resulting in loss of function or hyper-excitable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

describe pathology of MS

A

Results in plaques (areas of scarring).
Can occur in a number of different locations in the cns and different times.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

common locations of plaques

A
  1. optic tract
  2. spinal cord
  3. brain stem
  4. basal ganglia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HOW

Supporting diagnosis and monitoring

A

MRI - to identify plaques

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

symptoms of MS

Methyl prednisolone works for noone

A

very common: pain, numbness, walking difficulty, muscle spasms, fatigue,

common: Depression, headache, dizziness, cognitive impairment

less common: visual problems, itching, tremor

rare: seizures, hearing problems, breathing difficulty

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

general

MS risk factors

A

Genetic + enviromental factors
Age: 25-40
obesity: alter inflamatory response
sex: higher risk in females (hormonal, not chromosome related)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

enviromental

MS risk factors

A

Epstein-barr virus
smoking
latitude
vitamin D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Development of MS

A

Genetics/enviroment
>
Peripheral immune response with
activation and proliferation of self-reactive T-cells
>
Interaction with adhesion molecules on brain endothelial cells leads to crossing of the blood brain barrier (BBB)
>
Reactivation within the CNS leading to pro-inflammatory environment recruitment of more B cells, macrophages, microglia resulting in autoimmune demyelination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Relapsing/remitting MS (RRMS)

A

Periods of disability (relapse) with a stable periods of recovery (remission)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Secondary progressive MS (SPMS)

A

RMPS often (~50%) followed by slowly progressive clinical course known as Secondary Progressive (SP-MS)
* No longer have relapses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Benign form of MS

A

relapsing/remitting pattern but will make a full recovery from each episode

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Primary progressive MS (PPMS)

A

Around 10% of patients will have steady progress over time Primary Progressive multiple sclerosis (PP-MS)
* Won’t have relapses early in disease course

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Relapse periods

A

-symptoms arrise because myelin and oligodendrocytes are destroyed resluting in blocked/slowed nerve transmission
- The location of the plaques will determine the symptoms of MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Remission periods

A

the limited ability of the CNS to repair or replace damage but more a reflection of the CNS redirecting signals through alternate routes

17
Q

D

Diagnosis of MS

A
  • no specific tests available
  • neurologist
  • 2 or more relapses in the last 2 years
  • 2 or more clinically defined lesions
  • mri supports diagnosis
18
Q

Diagnosis of MS

supporting eveidence

A
  • MRI to locate/identify lesions
  • evoked potentials (neuronal stimulation to test transmition speed/strength)
  • lumbar puncture
19
Q

treatment of acute relapses

A

Oral/IV corticosteroids used to shorten the duration of relapse
1. Oral methylprenisolone: 0.5g for Five days as close to start of relapse as possible. no less than 0.5g
2. IV methylprednisolone: 1g DAILY for 3-5 days. in those whom oral corticosteroids have failed / not tolerated and hospital admission required

side effects:anxiety, insomnia, restlesness, depression, psychosis or euphoria

RAID

20
Q

Disease modifying therapies (DMT)

A
  • Drugs that will effect or modify the course of MS
  • surpress the inflamatory responses and immune reponses against myelein at range of sites
  • NOT A CURE but can reduce the number and severity of attacks

Reduce relapse and prolong remission

21
Q

NICE guidlines on: glatiramer acetate and interferon beta

A

Can no longer be reccomended but should stay on treatment until a suitable alternative is identified for those already started on these drugs.

22
Q

DMT drugs

A
  • Dimethyl fumurate: for RRMS but not active or rapidly progressing
  • Significantly reduced the annulized relapse rate and GD enhanced lesions.
  • Alemtuzumab: for treating adults with RRMS
23
Q

Mechanisms and effectivness of dmt for ms

F

A

Flingolimod: used in treatment of highly active RRMS in adults if an unchanged or increased relapse rate or ongoing sever relapses compared to the previous year despite beta interferon treatment.

24
Q

Mechanisms and effectivness of dmt for ms

N A C O

A
  1. Natalizumab - for the treatment of only rapidly evolving severe MS. Reduces ARR by 60% and gd lesions by 80%
  2. Alemtuzumab - for treating adults with active RRMS. upto 78% of patients were relapse free for 2 years
  3. Cladribine - targets lymphocytes and surpresses the immune system (SPMS)
  4. Ocrelizumab - targets B lymphocytes and acts as immunosupressive drug (PPMS)
25
Q

Limitations of DMT

A
  1. not established if long term time course of MS is significantly altered
  2. Long term use of antibody based treatment results in antibody resistence by the body reducing effectivness
  3. range of serious side effects: fever, myalgia, pain/swelling at site of injection, depression
26
Q

Management of muscle spasms in MS

A

1st line: baclofen, gabapentin
2nd line: Tizanidine / Dantrolene
3rd line: Benzodiazepines

27
Q

When will muscle relaxants be used to treat MS symptoms

A

spasms due to changes in CNS, NOT due to demyelination of peripheral motor nerve

28
Q

Management of Pain in MS

A

neuropathic: amitriptyline, duloxetine (SNRI), gabapentin, pregablin, as initial treatment

Pain:
Anticonvulsants; carbemazepine, phenytoin
antidepressent tricyclics; imiprimine, amitryptiline

29
Q

Management of bladder dysfunction in MS

A

Anticholonergic: oxybutinin, tolterodine
desmopressin
catheter

Clinical Therapeutics (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions